Common mechanisms of secondary endocrine resistance in advanced ER+ breast cancer
Common mechanisms of secondary endocrine resistance in advanced ER+ breast cancer. Aberrant activation of RTKs (HER2, IGFR1, FGFR, EGFR) by mutations or amplifications leads to activation of the PI3K and MAPK signaling pathways. NF1 loss-of-function mutations result in constitutively active RAS leading to downstream activation of both PI3K and MAPK pathways. PI3K and MAPK pathways activation induces ER phosphorylation and ligand-independent activation leading to transcription of ER-regulated genes despite estrogen blockade with endocrine therapy. Targeting upstream activation of RTKs (FGFR inhibition) or downstream oncogenic proteins of the PI3K pathway (AKT inhibition) and MAPK pathway (ERK inhibition) provides therapeutic options that can potentially overcome secondary endocrine resistance when combined with antiestrogen therapy. Point mutations of ER (ESR1 mutations) are another common mechanism of endocrine resistance rendering aromatase inhibitors ineffective. Oral SERDs ± targeted therapies present as an effective treatment option in ESR1 mutated tumors. CERANs, SERCAs, ShERPAs, and PROTACs are novel agents with therapeutic potential to overcome resistance to traditional endocrine therapies and are under development. NOTCH signaling upregulation has been shown to promote breast cancer stem-like cell expansion and its pharmacologic disruption can lead to reversal of resistance to antiestrogen therapy. AURKA overactivation has been linked to downregulation of estrogen receptors leading to endocrine resistance and worse prognosis. Novel agents targeting AURKA are being investigated as a potential therapeutic approach to overcome endocrine resistance. Abbreviations: AURKA, aurora kinase A; BRAF, v-raf murine sarcoma viral oncogene homolog B1; CERAN, Complete Estrogen Receptor Antagonist; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase; ER, estrogen receptor; ERE, estrogen receptor element; FGFR, fibroblast growth factor receptor; GTP, Guanosine-5’-triphosphate; HRAS, Hras proto-oncogene; HER, human epidermal growth factors receptor; IGFR, insulin-like growth factor; KRAS, Kirsten rat sarcoma virus; mTOR, mammalian target of rapamycin; MAP2K, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; NOTCH, notch signaling pathway; NF, nuclear factor; NRAS, neuroblastoma RAS viral oncogene Humalog; PROTAC, Proteolysis Targeting Chimera; PI3K, phosphoinositide 3-kinases; PTEN, phosphatase and TENsin homolog; RAS rat sarcoma signaling; Raf, rapidly accelerated fibrosarcoma; ShERPA, selective human estrogen receptor partial agonist; SERCA, selective estrogen receptor covalent antagonist
Publication
Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches (2023) Farah Raheem, et al. Int J Mol Sci. 2023 Nov;24(22). Figure: F2.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | HER2 | HER2 | ncbigene_synonym | ERBB2 | 2064 |
| Homo sapiens | Primates | PTEN | PTEN | ncbigene_symbol | PTEN | 5728 |
| Homo sapiens | Primates | AURKA | AURKA | ncbigene_symbol | AURKA | 6790 |
| Homo sapiens | Primates | Akt | AKT | ncbigene_synonym | AKT1 | 207 |
| Homo sapiens | Primates | Akt | AKT | famplex_relations | AKT2 | 208 |
| Homo sapiens | Primates | Akt | AKT | famplex_relations | AKT3 | 10000 |
| Homo sapiens | Primates | IGFR1 | IGFR1 | ncbigene_synonym | FCGR1A | 2209 |
| Homo sapiens | Primates | IGFR1 | IGFR1 | ncbigene_synonym | FCGR1BP | 2210 |
| Homo sapiens | Primates | IGFR1 | IGFR1 | ncbigene_synonym | FCGR1CP | 100132417 |
| Homo sapiens | Primates | IGFR | IGFR | ncbigene_synonym | IGF1R | 3480 |
| Homo sapiens | Primates | NOTCH | NOTCH | famplex_relations | NOTCH1 | 4851 |
| Homo sapiens | Primates | NOTCH | NOTCH | famplex_relations | NOTCH2 | 4853 |
| Homo sapiens | Primates | NOTCH | NOTCH | famplex_relations | NOTCH3 | 4854 |
| Homo sapiens | Primates | NOTCH | NOTCH | famplex_relations | NOTCH4 | 4855 |
| Homo sapiens | Primates | ERa | ERA | ncbigene_synonym | ESR1 | 2099 |
| Homo sapiens | Primates | ERa | ERA | ncbigene_synonym | ERAL1 | 26284 |
| Homo sapiens | Primates | FGFR | FGFR | famplex_relations | FGFR1 | 2260 |
| Homo sapiens | Primates | FGFR | FGFR | famplex_relations | FGFR2 | 2263 |
| Homo sapiens | Primates | FGFR | FGFR | famplex_relations | FGFR3 | 2261 |
| Homo sapiens | Primates | FGFR | FGFR | famplex_relations | FGFR4 | 2264 |
| Homo sapiens | Primates | FGFR | FGFR | famplex_relations | FGFRL1 | 53834 |
| Homo sapiens | Primates | EGFR | EGFR | ncbigene_symbol | EGFR | 1956 |
| Homo sapiens | Primates | NF1 | NF1 | ncbigene_symbol | NF1 | 4763 |
| Homo sapiens | Primates | RAS | RAS | famplex_relations | KRAS | 3845 |
| Homo sapiens | Primates | RAS | RAS | famplex_relations | HRAS | 3265 |
| Homo sapiens | Primates | RAS | RAS | famplex_relations | NRAS | 4893 |
| Homo sapiens | Primates | GTP | GTP | ncbigene_synonym | MTG1 | 92170 |
| Homo sapiens | Primates | Raf | RAF | ncbigene_synonym | ZHX2 | 22882 |
| Homo sapiens | Primates | Raf | RAF | famplex_relations | ARAF | 369 |
| Homo sapiens | Primates | Raf | RAF | famplex_relations | BRAF | 673 |
| Homo sapiens | Primates | Raf | RAF | famplex_relations | RAF1 | 5894 |
| Homo sapiens | Primates | MEK | MEK | ncbigene_synonym | MAP2K7 | 5609 |
| Homo sapiens | Primates | MEK | MEK | famplex_relations | MAP2K1 | 5604 |
| Homo sapiens | Primates | MEK | MEK | famplex_relations | MAP2K2 | 5605 |
| Homo sapiens | Primates | mTOR | MTOR | ncbigene_symbol | MTOR | 2475 |
| Homo sapiens | Primates | ERK | ERK | ncbigene_synonym | EPHB2 | 2048 |
| Homo sapiens | Primates | ERK | ERK | ncbigene_synonym | MAPK1 | 5594 |
| Homo sapiens | Primates | ERK | ERK | famplex_relations | MAPK3 | 5595 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| ERa | ERA | chebi:51451 | ||
| ERa | ERA | chebi:51451 | ||
| RAS | RAS | (1R)-N-(prop-2-yn-1-yl)indan-1-amine | chebi:63620 | |
| GTP | GTP | GTP | chebi:37565 | |
| MEK | MEK | butan-2-one | chebi:28398 | |
| ERa | ERA | chebi:51451 | ||
| ERa | ERA | chebi:51451 | ||
| ERa | ERA | chebi:51451 | ||
| ERa | ERA | chebi:51451 | ||
| Drugs | drugs | chebi:23888 | ||
| Nucleus | nucleus | nucleus | chebi:33252 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|